No abstract

The updated results of the precise measurements of the processes e + e − → ρ → π + π − , e + e − → ω → π + π − π 0 and e + e − → φ → K 0 L K 0 S performed by the CMD-2 collaboration are presented. The update appeared necessary due an overestimate of the integrated luminosity in previous analyses.

The cross section of the process e + e − → π + π − has been measured using about 114000 events collected by the CMD-2 detector at the VEPP-2M e + e − collider in the center-of-mass energy range from 0.61 to 0.96 GeV. Results of the pion form factor determination with a 0.6% systematic uncertainty are presented. The following values of the ρ-and ω-meson parameters were found: M ρ = (776.09± 0.81) MeV, Γ ρ = (144.46 ± 1.55) MeV, Γ(ρ → e + e − ) = (6.86 ± 0.12) keV, Br(ω → π + π − ) = (1.33 ± 0.25)%. Implications for the hadronic contribution to the muon

The principle of magnetic drug targeting, wherein therapy is attached to magnetically responsive carriers and magnetic fields are used to direct that therapy to disease locations, has been around for nearly two decades. Yet our ability to safely and effectively direct therapy to where it needs to go, for instance to deep tissue targets, remains limited. To date, magnetic targeting methods have not yet passed regulatory approval or reached clinical use. Below we outline key challenges to magnetic targeting, which include designing and selecting magnetic carriers for specific clinical indications, safely and effectively reaching targets behind tissue and anatomical barriers, real-time carrier imaging, and magnet design and control for deep and precise targeting. Addressing these challenges will require interactions across disciplines. Nanofabricators and chemists should work with biologists, mathematicians and engineers to better understand how carriers move through live tissues and how to optimize carrier and magnet designs to better direct therapy to disease targets. Clinicians should be involved early on and throughout the whole process to ensure the methods that are being developed meet a compelling clinical need and will be practical in a clinical setting. Our hope is that highlighting these challenges will help researchers translate magnetic drug targeting from a novel concept to a clinically-available treatment that can put therapy where it needs to go in human patients.

No abstract